| 1 Tardive dyskinesia: no clinically important improvement (medium term) |
1 |
42 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.45 [0.23, 0.89] |
| 2 Tardive dyskinesia: average endpoint score (AIMS, high = poor) (medium term) |
1 |
42 |
Mean Difference (IV, Fixed, 95% CI) |
‐5.5 [‐8.60, ‐2.40] |
| 3 General mental state: average endpoint score (BPRS, high = poor) (medium term) |
1 |
42 |
Mean Difference (IV, Fixed, 95% CI) |
‐4.30 [‐10.48, 1.88] |
| 4 Acceptability of the treatment: leaving the study early (medium term) |
1 |
50 |
Risk Ratio (IV, Fixed, 95% CI) |
0.6 [0.16, 2.25] |
| 5 Adverse effects: use of antiparkinsonism drugs (medium term) |
1 |
48 |
Risk Ratio (IV, Fixed, 95% CI) |
2.08 [0.74, 5.86] |
| 5.1 Haloperidol |
1 |
12 |
Risk Ratio (IV, Fixed, 95% CI) |
2.0 [0.56, 7.09] |
| 5.2 Risperidone |
1 |
36 |
Risk Ratio (IV, Fixed, 95% CI) |
2.26 [0.37, 13.60] |
| 6 Adverse effects: parkinsonism ‐ average endpoint score (ESRS) (medium term) |
1 |
42 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.40 [‐1.25, 0.45] |
| 7 Adverse effects: dystonia ‐ average endpoint score (ESRS) (medium term) |
1 |
42 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.70 [‐1.76, 0.36] |
